173 related articles for article (PubMed ID: 27136318)
1. Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer.
Zecchin C; Gueorguieva I; Enas NH; Friberg LE
Br J Clin Pharmacol; 2016 Sep; 82(3):717-27. PubMed ID: 27136318
[TBL] [Abstract][Full Text] [Related]
2. The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.
Safra T; Asna N; Veizman A; Shpigel S; Matcejevsky D; Inbar M; Grisaru D
Anticancer Drugs; 2014 Mar; 25(3):340-5. PubMed ID: 24185383
[TBL] [Abstract][Full Text] [Related]
3. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
Gordon AN; Teneriello M; Janicek MF; Hines J; Lim PC; Chen MD; Vaccarello L; Homesley HD; McMeekin S; Burkholder TL; Wang Y; Zhao L; Orlando M; Obasaju CK; Gill JF; Tai DF
Gynecol Oncol; 2011 Dec; 123(3):479-85. PubMed ID: 21978765
[TBL] [Abstract][Full Text] [Related]
4. Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft Studies.
Garcia-Cremades M; Pitou C; Iversen PW; Troconiz IF
AAPS J; 2019 Jan; 21(2):23. PubMed ID: 30706160
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute.
Hainsworth JD; Thompson DS; Bismayer JA; Gian VG; Merritt WM; Whorf RC; Finney LH; Dudley BS
Cancer Med; 2015 May; 4(5):673-81. PubMed ID: 25556916
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
Pignata S; Scambia G; Savarese A; Breda E; Sorio R; Pisano C; Lorusso D; Cognetti F; Vernaglia Lombardi A; Gebbia V; Scollo P; Morabito A; Signoriello G; Perrone F
Oncology; 2009; 76(1):49-54. PubMed ID: 19039248
[TBL] [Abstract][Full Text] [Related]
7. The role of gemcitabine in first-line treatment of advanced ovarian carcinoma.
Thigpen T
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S26-32. PubMed ID: 16716800
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.
Sufliarsky J; Chovanec J; Svetlovska D; Minarik T; Packan T; Kroslakova D; Lalabova R; Helpianska L; Horvathova D; Sevcik L; Spacek J; Laluha A; Tkacova V; Malec V; Rakicka G; Magdin D; Jancokova I; Dorr A; Stresko M; Habetinek V; Koza I
Neoplasma; 2009; 56(4):291-7. PubMed ID: 19473054
[TBL] [Abstract][Full Text] [Related]
9. Effects of sequential paclitaxel-carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study.
Wang F; Du X; Li X; Liu N; Yu H; Sheng X
Medicine (Baltimore); 2016 Dec; 95(51):e5696. PubMed ID: 28002342
[TBL] [Abstract][Full Text] [Related]
10. Dose-dense approaches to ovarian cancer treatment.
Katsumata N
Curr Treat Options Oncol; 2015 May; 16(5):21. PubMed ID: 25859831
[TBL] [Abstract][Full Text] [Related]
11. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
Trials; 2015 Dec; 16():575. PubMed ID: 26673577
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer.
Sorbe B; Graflund M; Horvath G; Swahn M; Boman K; Bangshöj R; Lood M; Malmström H
Int J Gynecol Cancer; 2012 Jan; 22(1):47-53. PubMed ID: 22193643
[TBL] [Abstract][Full Text] [Related]
13. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP
Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572
[TBL] [Abstract][Full Text] [Related]
14. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
15. First-line gemcitabine and carboplatin in advanced ovarian carcinoma: a phase II study.
Tay SK; Ilanchadran A; Tan TY
BJOG; 2006 Dec; 113(12):1388-92. PubMed ID: 17081186
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
Katsumata N; Yasuda M; Isonishi S; Takahashi F; Michimae H; Kimura E; Aoki D; Jobo T; Kodama S; Terauchi F; Sugiyama T; Ochiai K;
Lancet Oncol; 2013 Sep; 14(10):1020-6. PubMed ID: 23948349
[TBL] [Abstract][Full Text] [Related]
17. Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer.
Tate SC; Andre V; Enas N; Ribba B; Gueorguieva I
Eur J Cancer; 2016 Oct; 66():95-103. PubMed ID: 27544929
[TBL] [Abstract][Full Text] [Related]
18. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.
du Bois A; Herrstedt J; Hardy-Bessard AC; Müller HH; Harter P; Kristensen G; Joly F; Huober J; Avall-Lundqvist E; Weber B; Kurzeder C; Jelic S; Pujade-Lauraine E; Burges A; Pfisterer J; Gropp M; Staehle A; Wimberger P; Jackisch C; Sehouli J
J Clin Oncol; 2010 Sep; 28(27):4162-9. PubMed ID: 20733132
[TBL] [Abstract][Full Text] [Related]
19. Future directions in the chemotherapy of ovarian cancer.
Ozols RF
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-86-S15-90. PubMed ID: 9346230
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer.
Pfisterer J; Vergote I; Du Bois A; Eisenhauer E; ; ;
Int J Gynecol Cancer; 2005; 15 Suppl 1():36-41. PubMed ID: 15839957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]